Taiwan · Delayed Price · Currency is TWD Maxigen Biotech Statistics
Total Valuation
Maxigen Biotech has a market cap or net worth of TWD 3.59 billion. The enterprise value is 2.69 billion.
| Market Cap | 3.59B |
| Enterprise Value | 2.69B |
Important Dates
The next estimated earnings date is Wednesday, November 11, 2026.
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | Sep 1, 2026 |
Share Statistics
Maxigen Biotech has 89.68 million shares outstanding. The number of shares has increased by 0.33% in one year.
| Current Share Class | 89.68M |
| Shares Outstanding | 89.68M |
| Shares Change (YoY) | +0.33% |
| Shares Change (QoQ) | -0.38% |
| Owned by Insiders (%) | 0.98% |
| Owned by Institutions (%) | 2.04% |
| Float | 42.72M |
Valuation Ratios
The trailing PE ratio is 12.43.
| PE Ratio | 12.43 |
| Forward PE | n/a |
| PS Ratio | 4.28 |
| PB Ratio | 2.39 |
| P/TBV Ratio | 2.39 |
| P/FCF Ratio | 14.72 |
| P/OCF Ratio | 10.72 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.23, with an EV/FCF ratio of 11.04.
| EV / Earnings | 9.24 |
| EV / Sales | 3.21 |
| EV / EBITDA | 9.23 |
| EV / EBIT | 10.56 |
| EV / FCF | 11.04 |
Financial Position
The company has a current ratio of 2.33, with a Debt / Equity ratio of 0.07.
| Current Ratio | 2.33 |
| Quick Ratio | 2.13 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 0.34 |
| Debt / FCF | 0.41 |
| Interest Coverage | 1,274.09 |
Financial Efficiency
Return on equity (ROE) is 20.00% and return on invested capital (ROIC) is 33.13%.
| Return on Equity (ROE) | 20.00% |
| Return on Assets (ROA) | 8.55% |
| Return on Invested Capital (ROIC) | 33.13% |
| Return on Capital Employed (ROCE) | 16.95% |
| Weighted Average Cost of Capital (WACC) | 6.19% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.45 |
| Inventory Turnover | 3.06 |
Taxes
In the past 12 months, Maxigen Biotech has paid 33.73 million in taxes.
| Income Tax | 33.73M |
| Effective Tax Rate | 10.38% |
Stock Price Statistics
The stock price has decreased by -4.77% in the last 52 weeks. The beta is 0.38, so Maxigen Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.38 |
| 52-Week Price Change | -4.77% |
| 50-Day Moving Average | 39.76 |
| 200-Day Moving Average | 41.92 |
| Relative Strength Index (RSI) | 57.87 |
| Average Volume (20 Days) | 89,273 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Maxigen Biotech had revenue of TWD 837.44 million and earned 291.20 million in profits. Earnings per share was 3.22.
| Revenue | 837.44M |
| Gross Profit | 585.43M |
| Operating Income | 254.82M |
| Pretax Income | 324.92M |
| Net Income | 291.20M |
| EBITDA | 291.32M |
| EBIT | 254.82M |
| Earnings Per Share (EPS) | 3.22 |
Balance Sheet
The company has 997.27 million in cash and 100.00 million in debt, with a net cash position of 897.27 million or 10.01 per share.
| Cash & Cash Equivalents | 997.27M |
| Total Debt | 100.00M |
| Net Cash | 897.27M |
| Net Cash Per Share | 10.01 |
| Equity (Book Value) | 1.50B |
| Book Value Per Share | 16.67 |
| Working Capital | 706.35M |
Cash Flow
In the last 12 months, operating cash flow was 334.74 million and capital expenditures -91.10 million, giving a free cash flow of 243.64 million.
| Operating Cash Flow | 334.74M |
| Capital Expenditures | -91.10M |
| Depreciation & Amortization | 36.50M |
| Net Borrowing | 100.00M |
| Free Cash Flow | 243.64M |
| FCF Per Share | 2.72 |
Margins
Gross margin is 69.91%, with operating and profit margins of 30.43% and 34.77%.
| Gross Margin | 69.91% |
| Operating Margin | 30.43% |
| Pretax Margin | 38.80% |
| Profit Margin | 34.77% |
| EBITDA Margin | 34.79% |
| EBIT Margin | 30.43% |
| FCF Margin | 29.09% |
Dividends & Yields
This stock pays an annual dividend of 2.00, which amounts to a dividend yield of 4.97%.
| Dividend Per Share | 2.00 |
| Dividend Yield | 4.97% |
| Dividend Growth (YoY) | 140.93% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 25.56% |
| Buyback Yield | -0.33% |
| Shareholder Yield | 4.64% |
| Earnings Yield | 8.12% |
| FCF Yield | 6.79% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 7, 2023. It was a forward split with a ratio of 1.05.
| Last Split Date | Sep 7, 2023 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |